The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Leber Congenital Amaurosis Market Expected To Change From 2026 To 2030?
The leber congenital amaurosis market has demonstrated substantial expansion in recent years. This market is set to increase from $1.06 billion in 2025 to $1.12 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. The notable growth observed historically stems from elements like the scarcity of treatment options for inherited retinal disorders, greater recognition of rare genetic eye conditions, progress in retinal imaging technologies, an expansion in pediatric ophthalmology services, and foundational research into gene replacement therapy.
The leber congenital amaurosis market is anticipated to experience robust expansion over the coming years. It is projected to reach $1.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period is attributable to several factors, including increased investment in ophthalmic gene therapy research, the broadening scope of precision medicine initiatives, a rise in regulatory approvals for rare disease treatments, the wider uptake of advanced genetic testing, and enhanced healthcare access for rare genetic disorders. Key trends anticipated in the same period encompass the increasing number of gene therapy approvals for inherited retinal conditions, a heightened emphasis on early genetic screening and diagnosis, an expansion in clinical trials for innovative retinal regeneration treatments, a growing embrace of assistive vision technologies, and progress in retinal prosthesis and bionic eye solutions.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp
Which Primary Drivers Are Impacting The Leber Congenital Amaurosis Market Growth?
The rising occurrence of inherited retinal disorders is projected to boost the expansion of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are defined as genetic conditions impacting the retina, which is the light-sensitive tissue located at the back of the eye crucial for sight. The growth in inherited retinal diseases can be linked to enhancements in genetic testing, increased awareness and diagnostic capabilities, and extended life spans. Progress in genetic testing has facilitated the diagnosis of inherited retinal diseases, resulting in the detection of a greater number of cases. Leber congenital amaurosis contributes to a deeper comprehension of inherited retinal diseases by uncovering genetic mutations and mechanisms of the disease, which aids in the creation of targeted therapies and interventions. For example, data from January 2025, provided by the UK Parliament’s House of Commons Library, a UK-based government body, indicated that around 25,000 individuals in the UK suffered from inherited retinal diseases in 2024, representing an annual rise of 2%. Consequently, the growing incidence of inherited retinal diseases is a key driver for the leber congenital amaurosis market.
How Is The Leber Congenital Amaurosis Market Segmented Across Different Segment Categories?
The leber congenital amaurosis market covered in this report is segmented –
1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments
2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
3) By Distribution Channel: Direct Tender, Retail Sales
4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users
Subsegments:
1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies
2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies
3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology
4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment
5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions
Which Trends Are Shaping Growth In The Leber Congenital Amaurosis Market?
Leading companies in the leber congenital amaurosis market are concentrating on developing innovative solutions, such as RNA-based treatments, to enhance vision restoration and disease management. RNA-based treatments utilize RNA molecules to address diseases by targeting genetic processes, including mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Théa S.A.S., a France-based pharmaceutical company, introduced Sepul Bio, a dedicated business unit focused on advancing RNA therapies for inherited retinal diseases, specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. With the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is set to achieve significant progress in managing these rare genetic disorders.
Which Organizations Play A Role In The Leber Congenital Amaurosis Market Landscape?
Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.
Get The Full Leber Congenital Amaurosis Market Report:
https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report
Which Region Leads The Leber Congenital Amaurosis Market In Terms Of Market Share?
North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Leber Congenital Amaurosis Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report
Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2026, By The Business Research Company
Congenital Heart Disease Chd Market Report 2026
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report
Progressive Multifocal Leukoencephalopathy Treatment Market Report
Gauchers Disease Market Report
https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model